GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (NAS:EXAS) » Definitions » Piotroski F-Score

Exact Sciences (Exact Sciences) Piotroski F-Score : 5 (As of Apr. 30, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Exact Sciences Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Exact Sciences has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Exact Sciences's Piotroski F-Score or its related term are showing as below:

EXAS' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 5
Current: 5

During the past 13 years, the highest Piotroski F-Score of Exact Sciences was 5. The lowest was 2. And the median was 4.


Exact Sciences Piotroski F-Score Historical Data

The historical data trend for Exact Sciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Piotroski F-Score Chart

Exact Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 4.00 3.00 2.00 5.00

Exact Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 4.00 5.00 5.00 5.00

Competitive Comparison of Exact Sciences's Piotroski F-Score

For the Diagnostics & Research subindustry, Exact Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exact Sciences's Piotroski F-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Exact Sciences's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -74.151 + -81.026 + 0.794 + -49.766 = $-204 Mil.
Cash Flow from Operations was -38.215 + 100.424 + 24.361 + 69.549 = $156 Mil.
Revenue was 602.45 + 622.093 + 628.338 + 646.885 = $2,500 Mil.
Gross Profit was 445.55 + 465.093 + 459.812 + 475.068 = $1,846 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(6226.873 + 6304.328 + 6355.563 + 6420.83 + 6471.334) / 5 = $6355.7856 Mil.
Total Assets at the begining of this year (Dec22) was $6,227 Mil.
Long-Term Debt & Capital Lease Obligation was $2,475 Mil.
Total Current Assets was $1,194 Mil.
Total Current Liabilities was $515 Mil.
Net Income was -180.937 + -166.063 + -148.761 + -127.745 = $-624 Mil.

Revenue was 486.571 + 521.64 + 523.073 + 552.995 = $2,084 Mil.
Gross Profit was 351.871 + 377.04 + 375.136 + 405.837 = $1,510 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(6684.884 + 6490.537 + 6437.155 + 6306.566 + 6226.873) / 5 = $6429.203 Mil.
Total Assets at the begining of last year (Dec21) was $6,685 Mil.
Long-Term Debt & Capital Lease Obligation was $2,419 Mil.
Total Current Assets was $982 Mil.
Total Current Liabilities was $413 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Exact Sciences's current Net Income (TTM) was -204. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Exact Sciences's current Cash Flow from Operations (TTM) was 156. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-204.149/6226.873
=-0.03278516

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-623.506/6684.884
=-0.09327103

Exact Sciences's return on assets of this year was -0.03278516. Exact Sciences's return on assets of last year was -0.09327103. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Exact Sciences's current Net Income (TTM) was -204. Exact Sciences's current Cash Flow from Operations (TTM) was 156. ==> 156 > -204 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=2475.346/6355.7856
=0.38946342

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=2418.505/6429.203
=0.37617493

Exact Sciences's gearing of this year was 0.38946342. Exact Sciences's gearing of last year was 0.37617493. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=1194.369/514.701
=2.32051035

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=982.257/412.747
=2.37980409

Exact Sciences's current ratio of this year was 2.32051035. Exact Sciences's current ratio of last year was 2.37980409. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Exact Sciences's number of shares in issue this year was 181.125. Exact Sciences's number of shares in issue last year was 177.599. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1845.523/2499.766
=0.7382783

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1509.884/2084.279
=0.72441549

Exact Sciences's gross margin of this year was 0.7382783. Exact Sciences's gross margin of last year was 0.72441549. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=2499.766/6226.873
=0.40144805

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=2084.279/6684.884
=0.31178985

Exact Sciences's asset turnover of this year was 0.40144805. Exact Sciences's asset turnover of last year was 0.31178985. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+1+1+0+0+0+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Exact Sciences has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Exact Sciences  (NAS:EXAS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Exact Sciences Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Exact Sciences's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Exact Sciences (Exact Sciences) Business Description

Traded in Other Exchanges
Address
5505 Endeavor Lane, Madison, WI, USA, 53719
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
Executives
Brian Baranick officer: Gen. Mgr., Precision Oncology 441 CHARMANY DRIVE, MADISON WI 53719
Sarah Condella officer: SVP, Human Resources 441 CHARMANY DRIVE, MADISON WI 53719
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Everett Cunningham officer: Chief Commercial Officer C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Jeffrey Thomas Elliott officer: Chief Financial Officer 5505 ENDEAVOR LANE, MADISON WI 53719
James Edward Doyle director 5505 ENDEAVOR LANE, MADISON WI 53719
James Herriott officer: General Counsel 5505 ENDEAVOR LANE, MADISON WI 53719
Katherine S Zanotti director 431 E 9TH STREET, HINSDALE IL 60521
Jacob A Orville officer: General Manager, New Ventures 5505 ENDEAVOR LANE, MADISON WI 53719
Kevin T Conroy director, officer: Vice President 5505 ENDEAVOR LANE, MADISON WI 53719
D Scott Coward officer: SVP and General Counsel 441 CHARMANY DRIVE, MADISON WI 53719
Paul J Clancy director C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Graham Peter Lidgard officer: SVP, Chief Scientific Officer 5505 ENDEAVOR LANE, MADISON WI 53719
Michael S Wyzga director RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139
Torsten Hoof officer: General Manager, International 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063